Novartis and Versant to form biotech venture Borealis Biosciences
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Subscribe To Our Newsletter & Stay Updated